Profil
David Yeomans is the founder of SiteOne Therapeutics, Inc. founded in 2010 and Trigemina, Inc. founded in 2006, where he holds the title of Chief Scientist from 2006 to present.
Postes actifs de David Yeomans
| Sociétés | Poste | Début |
|---|---|---|
SiteOne Therapeutics, Inc.
 SiteOne Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology SiteOne Therapeutics, Inc. develops novel pain therapeutics and diagnostics. Its therapeutic candidates are selective inhibitors of a voltage-gated sodium ion channel. The company was founded by Sandip Biswal, Justin Du Bois, George Miljanich, John Mulcahy and David Yeomans in 2010 and is headquartered in Bozeman, MT. | Fondateur | 01/01/2010 |
Trigemina, Inc.
 Trigemina, Inc. Pharmaceuticals: MajorHealth Technology Trigemina, Inc. develops drugs to control pain and migraine headache. Its platform is based on proprietary formulations of oxytocin, a naturally-occurring hormone, delivered through nasal-cerebral pathways for the treatment of a large spectrum of chronic and acute neurological disorders. The company was founded by David C. Yeomans in 2006 and is headquartered in Moraga, CA. | Fondateur | 01/01/2006 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
SiteOne Therapeutics, Inc.
SiteOne Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology SiteOne Therapeutics, Inc. develops novel pain therapeutics and diagnostics. Its therapeutic candidates are selective inhibitors of a voltage-gated sodium ion channel. The company was founded by Sandip Biswal, Justin Du Bois, George Miljanich, John Mulcahy and David Yeomans in 2010 and is headquartered in Bozeman, MT. | Health Technology |
Trigemina, Inc.
Trigemina, Inc. Pharmaceuticals: MajorHealth Technology Trigemina, Inc. develops drugs to control pain and migraine headache. Its platform is based on proprietary formulations of oxytocin, a naturally-occurring hormone, delivered through nasal-cerebral pathways for the treatment of a large spectrum of chronic and acute neurological disorders. The company was founded by David C. Yeomans in 2006 and is headquartered in Moraga, CA. | Health Technology |
